AI-Powered Stock Analysis & Investment Research

Analyze over 5,500 stocks using cutting-edge AI tools. Get real-time market insights, deep company fundamentals, and smarter investment decisions.

Screener Image

Direct Access To the Stock market

Trending Investment Case Today

Stock-Card

FICO

+5.99%
Stock-Card

GWRE

+6.02%
Stock-Card

PSTG

+8.46%
Stock-Card

REZI

+14.39%
Stock-Card

HUBS

+5.63%
Stock-Card

AA

+5.68%
Stock-Card

GLW

+5.82%

How to find the best strategy for you ?

Card image cap

Value

Our factor investing score meticulously assesses the intrinsic value of each asset, providing invaluable insights into its potential for long-term growth.

Card image cap

Growth

With a keen focus on growth prospects, our factor investing score analyzes each asset's trajectory, offering strategic guidance for maximizing returns in dynamic market conditions..

Card image cap

Quality

With an emphasis on quality metrics, our factor investing score meticulously evaluates the fundamental strength and stability of each asset, safeguarding your portfolio against potential risks.

Card image cap

Volatility

By meticulously evaluating volatility, our factor investing score helps you navigate market turbulence, ensuring a balanced portfolio resilient to unpredictable fluctuations.

Card image cap

Momentum

Leveraging momentum analysis, our factor investing score identifies assets poised for upward trends, empowering you to capitalize on market momentum for optimized performance.

Card image cap

Yield

Focused on yield optimization, our factor investing score identifies assets with attractive income potential, enabling you to construct a diversified portfolio tailored to your income objectives.

Create a reliable strategy with the A-Score

Undervalued company with stable and reliable business like Warren Buffet

Get detailled Investment Case for more than 5500 Stocks

Image

Strong Company Updates

Get a complete corporate access : reliable, clear, and always available at the time you need it

Stock-Card
Earnings

SPX Technologies(SPXC): SPX Technologies' Strong Q4 2025 Earnings: A Closer Look

SPX Technologies reported a robust fourth quarter 2025, with revenue growing 19.4% year-over-year, driven by recent acquisitions and organic growth in both segments. Adjusted EBITDA increased by approximately 22% year-over-year, with 50 basis points of margin expansion. The company's adjusted EPS came in at $1.6, slightly below estimates of $1.86. For the full year 2025, the company achieved 21% growth in adjusted EBITDA and adjusted EPS. The HVAC segment saw revenue grow by 16.4% year-over-year, with segment income increasing by $17 million, or 18%. As Eugene Joseph Lowe noted, "We had a strong close to the year, growing full year adjusted EBITDA and adjusted EPS by 21%."

550$ (-1.8%)

A-Score: 4.8/10

Feb -24
Stock-Card
Earnings

Cytokinetics(CYTK): Cytokinetics' MYCorzo Launch and Pipeline Advancements Drive Growth

Cytokinetics, Incorporated reported a net loss of $183 million, or $1.50 per share, for Q4 2025, compared to a net loss of $150 million, or $1.26 per share, in Q4 2024. Total revenues in Q4 2025 were $17.8 million, and total revenues for the full year 2025 were $88 million. The actual EPS came in at -$1.5, slightly worse than estimates of -$1.48. Research and development expenses for Q4 2025 were $104.4 million, up from $93.6 million in Q4 2024, driven by advancing clinical trials and higher personnel costs.

550$ (-1.8%)

A-Score: 4.0/10

Feb -24
Stock-Card
Earnings

First Solar(FSLR): First Solar's Q4 and Full-Year 2025 Earnings: A Strong Performance

First Solar reported a robust financial performance for Q4 and full-year 2025, with net sales reaching $1.7 billion in Q4 and $5.2 billion for the full year, representing a 24% year-over-year increase driven primarily by a rise in module volume. The company's gross margin expanded, and earnings per diluted share were $4.84 in Q4, slightly below estimates of $5.22. For the full year, EPS was $14.21, within the guidance range.

550$ (-1.8%)

A-Score: 4.9/10

Feb -24
Register Now

Quality Equity Research. Easy Access

Get started with our cost-effective equity research

Monthly Annual Up to 30% Discount

Free Trial

FREE
7 Days
  • Unlimited access to Watchlist
  • Unlimited access to screener
  • Unlimited access to AI Assistant
  • Access to US Investment Case
  • API calls limited to 10/day
  • Request new coverage
  • Premium Support
Start Free Trial

Ultimate

$99.90
per month
  • Unlimited access to Watchlist
  • Unlimited access to screener
  • Unlimited access to AI Assistant
  • Unlimited access to Investment Case
  • API calls limited to 2500/minute
  • Request new coverage
  • Premium Support
Buy Now